{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:12:04Z","timestamp":1785334324792,"version":"3.55.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jbspin.2025.105978","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T05:00:41Z","timestamp":1758949241000},"page":"105978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vaccinating patients with autoimmune diseases"],"prefix":"10.1016","volume":"93","author":[{"given":"Ai Li","family":"Yeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2025.105978_bib0385","series-title":"Table 1. Summary of WHO position papers - Recommendations for routine immunization","year":"2025"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105978_bib0390","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccm.2024.10.013","article-title":"Pulmonary complications of biological therapies in inflammatory and autoimmune diseases","volume":"46","author":"Yeo","year":"2025","journal-title":"Clin Chest Med"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105978_bib0395","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105978_bib0400","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105978_bib0405","series-title":"Past seasons vaccine effectiveness estimates","year":"2025"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105978_bib0410","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2665-9913(19)30094-3","article-title":"Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial","volume":"2","author":"Colmegna","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105978_bib0415","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/cid\/ciae613","article-title":"Glucocorticoid dosing and implications for vaccination: evolution of global definitions","volume":"80","author":"Wang","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105978_bib0420","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.42318","article-title":"A multicenter, prospective, randomized <scp>Parallel-Group<\/scp> trial on the effects of temporary methotrexate discontinuation for one week versus two weeks on seasonal influenza vaccination in patients with rheumatoid arthritis","volume":"75","author":"Park","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105978_bib0425","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-012-9813-x","article-title":"Rituximab-treated patients have a poor response to influenza vaccination","volume":"33","author":"Eisenberg","year":"2013","journal-title":"J Clin Immunol"},{"issue":"10","key":"10.1016\/j.jbspin.2025.105978_bib0430","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105978_bib0435","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/acr.21838","article-title":"Abatacept and reduced immune response to pandemic 2009 influenza A\/H1N1 vaccination in patients with rheumatoid arthritis","volume":"65","author":"Ribeiro","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.jbspin.2025.105978_bib0440","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.jbspin.2025.105978_bib0445","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105978_bib0450","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/ard.2010.144451","article-title":"Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate","volume":"70","author":"Coulson","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105978_bib0455","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.jbspin.2025.105978_bib0460","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/art.30580","article-title":"Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors","volume":"63","author":"Kapetanovic","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105978_bib0465","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res Therap"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105978_bib0470","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/S2665-9913(24)00128-0","article-title":"Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case-control study","volume":"6","author":"Nakafero","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105978_bib0475","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/vaccines11030682","article-title":"SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic","volume":"11","author":"Chakraborty","year":"2023","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105978_bib0480","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.vaccine.2024.01.100","article-title":"COVID-19 vaccines and adverse events of special interest: a multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals","volume":"42","author":"Faksova","year":"2024","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105978_bib0485","first-page":"E1","article-title":"American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5","volume":"75","author":"Curtis","year":"2023","journal-title":"Arthr Rheumatol"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105978_bib0490","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1007\/s12325-023-02533-x","article-title":"Factors associated with severe COVID-19 among patients with rheumatoid arthritis: a large, nationwide electronic health record cohort study in the United States","volume":"40","author":"Ye","year":"2023","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.jbspin.2025.105978_bib0495","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S2665-9913(23)00160-1","article-title":"Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY","volume":"5","author":"Pearce","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"10.1016\/j.jbspin.2025.105978_bib0500","doi-asserted-by":"crossref","first-page":"e755","DOI":"10.1016\/S2665-9913(22)00228-4","article-title":"Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials","volume":"4","author":"Skaria","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105978_bib0505","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/S2665-9913(23)00298-9","article-title":"Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial","volume":"6","author":"Abhishek","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"32","key":"10.1016\/j.jbspin.2025.105978_bib0510","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged>=60 years: updated recommendations of the advisory committee on immunization practices\u2013United States, 2024","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"16","key":"10.1016\/j.jbspin.2025.105978_bib0515","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105978_bib0520","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3390\/vaccines13030328","article-title":"Immunogenicity and safety of the bivalent respiratory syncytial virus prefusion f subunit vaccine in immunocompromised or renally impaired adults","volume":"13","author":"Almeida","year":"2025","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105978_bib0525","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/vaccines12050500","article-title":"Efficacy of respiratory syncytial virus vaccination to prevent lower respiratory tract illness in older adults: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Ricco","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jbspin.2025.105978_bib0530","series-title":"Respiratory Syncytial Virus (RSV) Vaccine Safety: Post-licensure safety data","year":"2025"},{"issue":"21","key":"10.1016\/j.jbspin.2025.105978_bib0535","doi-asserted-by":"crossref","first-page":"489","DOI":"10.15585\/mmwr.mm7321a3","article-title":"Early safety findings among persons aged>=60 years who received a respiratory syncytial virus vaccine - United States, May 3, 2023-April 14, 2024","volume":"73","author":"Hause","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jbspin.2025.105978_bib0540","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pvr.2017.06.002","article-title":"HPV vaccination of immunocompromised hosts","volume":"4","author":"Garland","year":"2017","journal-title":"Papillomavirus Res"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105978_bib0545","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3390\/vaccines11091490","article-title":"HPV vaccination in immunosuppressed patients with established skin warts and non-melanoma skin cancer: a single-institutional cohort study","volume":"11","author":"Bossart","year":"2023","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.jbspin.2025.105978_bib0550","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105978_bib0555","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105978_bib0560","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000002216","article-title":"Disease safety, immunogenicity, and efficacy of recombinant herpes zoster vaccine (RZV or Shingrix) in autoimmune rheumatic diseases: launching a randomized phase 4 study","author":"Kupa","year":"2025","journal-title":"J Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.jbspin.2025.105978_bib0565","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.jbspin.2025.105978_bib0570","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center's experience with 400 patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"11","key":"10.1016\/j.jbspin.2025.105978_bib0575","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/art.42261","article-title":"Recombinant zoster vaccine uptake and risk of flares among older adults with immune-mediated inflammatory diseases in the US","volume":"74","author":"Leung","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105978_bib0580","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-025-03565-0","article-title":"Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster","volume":"27","author":"Curtis","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2025.105978_bib0585","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/annrheumdis-2024-eular.979","article-title":"POS0620 immunogenicity of the recombinant zoster vaccine in people with rheumatoid arthritis using abatacept","volume":"83","author":"Winthrop","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105978_bib0590","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2024-eular.763","article-title":"OP0020 Immunogenicity of an adjuvant recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomized substudy","volume":"83","author":"Winthrop","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jbspin.2025.105978_bib0595","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/infdis\/jit405","article-title":"Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009","volume":"208","author":"Weinmann","year":"2013","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.jbspin.2025.105978_bib0600","doi-asserted-by":"crossref","first-page":"ofz295","DOI":"10.1093\/ofid\/ofz295","article-title":"Varicella virus vaccine live: a 22-year review of postmarketing safety data","volume":"6","author":"Woodward","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105978_bib0605","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vaccine.2022.10.063","article-title":"Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions","volume":"41","author":"Sullivan","year":"2023","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jbspin.2025.105978_bib0610","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0961203320988601","article-title":"Routine testing for hyposplenism in a lupus clinic diagnoses; new cases and opportunities for intervention","volume":"30","author":"Ko","year":"2021","journal-title":"Lupus"},{"issue":"27","key":"10.1016\/j.jbspin.2025.105978_bib0615","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105978_bib0620","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2025.105978_bib0625","series-title":"Australian Immunisation Handbook, Table: Recommended timing of live vaccine administration for people receiving immunosuppressive therapies Canberra: Australian Government Department of Health and Aged Care","year":"2024"},{"issue":"22","key":"10.1016\/j.jbspin.2025.105978_bib0630","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older Adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jbspin.2025.105978_bib0635","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.7326\/M20-6928","article-title":"The safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy: a randomized controlled trial","volume":"174","author":"Curtis","year":"2021","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.jbspin.2025.105978_bib0640","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/art.40187","article-title":"The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"45","key":"10.1016\/j.jbspin.2025.105978_bib0645","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.15585\/mmwr.mm7345a4","article-title":"Progress toward measles elimination - worldwide, 2000-2023","volume":"73","author":"Minta","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1016\/j.jbspin.2025.105978_bib0650","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1136\/ard.2006.063586","article-title":"Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis","volume":"66","author":"Heijstek","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1016\/j.jbspin.2025.105978_bib0655","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1001\/jama.2013.6768","article-title":"Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial","volume":"309","author":"Heijstek","year":"2013","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.jbspin.2025.105978_bib0660","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.vaccine.2023.03.074","article-title":"Safety of measles-mumps-rubella booster vaccination in patients with juvenile idiopathic arthritis: a long-term follow-up study","volume":"41","author":"Hamad Saied","year":"2023","journal-title":"Vaccine"},{"issue":"RR\u201304","key":"10.1016\/j.jbspin.2025.105978_bib0665","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105978_bib0670","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2014-205455","article-title":"Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNFalpha therapy","volume":"73","author":"Schoffelen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jbspin.2025.105978_bib0675","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/cid\/cir234","article-title":"Follow-up of 686 patients with acute Q fever and detection of chronic infection","volume":"52","author":"van der Hoek","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jbspin.2025.105978_bib0680","series-title":"Australian Immunisation Handbook, Q fever","year":"2024"},{"key":"10.1016\/j.jbspin.2025.105978_bib0685","series-title":"Countries with risk of yellow fever transmission and countries requiring yellow fever vaccination (November 2022)","year":"2022"},{"issue":"17\u201318","key":"10.1016\/j.jbspin.2025.105978_bib0690","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.vaccine.2004.01.026","article-title":"Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX","volume":"22","author":"Kitchener","year":"2004","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.jbspin.2025.105978_bib0695","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1016\/j.vaccine.2014.08.051","article-title":"Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)","volume":"32","author":"Seligman","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105978_bib0700","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4269\/ajtmh.13-0542","article-title":"Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data","volume":"90","author":"Seligman","year":"2014","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105978_bib0705","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac095","article-title":"Yellow fever vaccine safety in immunocompromised individuals: a systematic review and, meta-analysis","volume":"30","author":"Wigg De Ara\u00fajo Lagos","year":"2023","journal-title":"J Travel Med"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105978_bib0710","doi-asserted-by":"crossref","DOI":"10.1186\/s42358-019-0056-x","article-title":"Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases","volume":"59","author":"Pileggi","year":"2019","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105978_bib0715","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3389\/fimmu.2020.01382","article-title":"Planned yellow fever primary vaccination is safe and immunogenic in patients with autoimmune diseases: a prospective non-interventional study","volume":"11","author":"Valim","year":"2020","journal-title":"Front Immunol"},{"issue":"32","key":"10.1016\/j.jbspin.2025.105978_bib0720","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1016\/j.vaccine.2021.06.023","article-title":"Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: a systematic review and network meta-analysis","volume":"39","author":"Furuya-Kanamori","year":"2021","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.jbspin.2025.105978_bib0725","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1016\/j.vaccine.2023.10.014","article-title":"A systematic literature review of the effectiveness of tick-borne encephalitis vaccines in Europe","volume":"41","author":"Angulo","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jbspin.2025.105978_bib0730","series-title":"Vaccines against tick-borne encephalitis: WHO position paper","first-page":"241","year":"2011"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105978_bib0735","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1093\/infdis\/jiae463","article-title":"Clinical characteristics of tick-borne encephalitis in adult patients: a 10-year retrospective study in Stockholm, Sweden","volume":"231","author":"Bartholdsson","year":"2025","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105978_bib0740","first-page":"855","article-title":"Fatal outcome of tick-borne encephalitis in two patients with rheumatic disease treated with rituximab","volume":"56","author":"Knight","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.jbspin.2025.105978_bib0745","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.vaccine.2024.01.022","article-title":"Immunogenicity of tick-borne-encephalitis-virus-(TBEV)-vaccination and impact of age on humoral and cellular TBEV-specific immune responses in patients with rheumatoid arthritis","volume":"42","author":"Rack","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.jbspin.2025.105978_bib0750","series-title":"Rabies. CDC Yellow Book: Health Information for International Travel [Internet]","author":"Wallace","year":"2024"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105978_bib0755","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3201\/eid1809.111833","article-title":"Inadequate antibody response to rabies vaccine in immunocompromised patient","volume":"18","author":"Kopel","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105978_bib0760","doi-asserted-by":"crossref","first-page":"taac148","DOI":"10.1093\/jtm\/taac148","article-title":"Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial","volume":"30","author":"Garcia Garrido","year":"2023","journal-title":"J Travel Med"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X2500140X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X2500140X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T20:02:31Z","timestamp":1772568151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X2500140X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1297319X2500140X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105978","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccinating patients with autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105978"}}